Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arava, Avandia's Divergent Paths: FDA Strengthens Arava Label Warning

This article was originally published in The Pink Sheet Daily

Executive Summary

As FDA advisory committee debated the fate of Avandia, the agency bolsters liver warning on Arava, another drug David Graham suggested be removed from the market.
Advertisement

Related Content

FDA Looked To Arava’s Safety Experience In Gauging Aubagio’s Risks
Avandia's TIDE May Come In Smaller
Grassley And Baucus Turn Up Heat On GSK With Attack On Avandia Data Handling
Avandia Safety Rhetoric Ramps Up Ahead Of Advisory Committee Review
Advisory Committee Rejects Avandia Vs. Actos Comparison Data
Grassley Stumbles In Comments On Meridia’s Regulatory History
First-Time Generics Of Sanofi-Aventis’ Arava Enter Market
Crestor, Serevent Safety Issues Push Vioxx Out Of Spotlight In Senate Hearing
Crestor, Serevent Safety Issues Push Vioxx Out Of Spotlight In Senate Hearing

Topics

Advertisement
UsernamePublicRestriction

Register

PS070906

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel